Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
52W High
$56.93
52W Low
$4.64
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
3.09
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.17
EV/Revenue (<3 favorable)
8.26
P/S (TTM) (<3 favorable)
163.32
P/B (<3 favorable)
1.09
Ownership
Institution‑heavySource: Overview
Insiders (1–5% typical)
0.71%
Institutions (25–75% balanced)
81.91%
Shares Outstanding
12,255,200
Float
7,542,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
-50,424,000
EPS (TTM)
-4.76
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.49%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—